The impact of Susan G. Komen-funded research on approved drugs for breast cancer treatment
Nonprofit and public sector research funding provide the foundation for the drug development pipeline. This paper highlights an innovative approach to assess the impact of research investments beyond traditional academic measures and underscores the significance of nonprofit, patient-centered organizations like Komen in driving drug development through supporting basic and applied research.
Authors
- Dana M. Brantley‐Sieders (ORCID: https://orcid.org/0000-0002-2751-6547)
- Kari Wojtanik (ORCID: https://orcid.org/0000-0003-2299-6112)
- Amy M. Dworkin
- Lauren Leslie
- Kimberly Sabelko
Institutions
- Susan G. Komen Breast Cancer Foundation (US)
Publication Details
- Journal
- Journal of Clinical and Translational Science
- Published
- 2025-12-12
- DOI
- https://doi.org/10.1017/cts.2025.10224
- Primary Topic
- Economic and Financial Impacts of Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00